MMS HOLDINGS JOINS DECENTRALIZED TRIALS & RESEARCH ALLIANCE (DTRA) AS A FOUNDING MEMBER TO ACCELERATE THE ADOPTION OF PATIENT-FOCUSED CLINICAL TRIALS
CANTON, Mich. (January 29, 2021) – MMS Holdings – an award-winning, data-focused CRO – joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized Trials & Research Alliance (DTRA),” which launched on December 10th, 2020, plans to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices, and new technologies in decentralized clinical research.
“As a specialized data services and technologies provider, MMS will help guide the life sciences industry into an exciting future where decentralized trials and research help the world find treatments and cures at a more rapid pace,” said Eric Harvey, Director of Biostatistics and Data Science, MMS. “We believe that innovation and growth has a place in every part of our industry, and the proliferation of decentralized clinical trials is set to become one of the biggest changes that we’ve seen in industry in the past decade.”
“We are extremely gratified to welcome MMS to the Decentralized Trials & Research Alliance,” said Amir Kalali, MD, founder of several collaborative life science communities, and co-convenor of DTRA. “By advancing decentralized research we can make the clinical trial process more patient-focused, increase trial efficiency and encourage use of technologies. We are excited by MMS’ commitment to embracing decentralized trials and to changing the culture that has been the rate limiter to innovation.”
Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years…